O

ORIC Pharmaceuticals

Clinical-stage oncology company targeting resistance

Vice President - Pharmacovigilance and Drug Safety, Head of Pharmacovigilance and Drug Safety

Biology & BiotechConfirmed live in the last 24 hours
Full-timeSan Diego, CA, USA$310k - $385k /yr

About the Job

Requirements

  • MD, DO, PharmD, PhD, or an equivalent advanced scientific or healthcare degree.
  • At least 12 years of progressive experience in pharmacovigilance, clinical safety, or drug development within the biotechnology or pharmaceutical industry.
  • Significant experience leading and managing a pharmacovigilance or patient safety function or team.
  • Demonstrated experience supporting investigational products across Phase 1–3 clinical development.
  • Deep knowledge of global pharmacovigilance regulations and guidelines, including FDA, EMA, ICH, and GCP requirements.
  • Experience with safety governance, benefit-risk assessment, signal detection, risk management plans, and inspection readiness.
  • A track record of successful health authority interactions and regulatory inspections.
  • Experience overseeing safety and pharmacovigilance vendors and CROs.
  • Strong strategic leadership, written and verbal communication, and cross-functional collaboration skills.
  • Ability to operate with a high level of autonomy and sound judgment in a fast-paced, growth-stage environment.

Responsibilities

  • Develop and execute ORIC’s global pharmacovigilance strategy in alignment with corporate objectives and applicable regulatory requirements.
  • Provide leadership for benefit-risk evaluation, safety surveillance, signal detection, signal management, and risk management across ORIC’s investigational products.
  • Own medical safety aspects of clinical development, including safety input into protocols, Investigator Brochures, clinical study reports, and regulatory submissions.
  • Lead the strategy for and drive safety-related content for protocols, Investigator Brochures, DSURs, PSURs, risk management plans, informed consent forms, reference safety information, clinical study reports, and regulatory filings.
  • Serve as a senior safety advisor to the Chief Medical Officer and represent Pharmacovigilance in governance committees and safety review meetings.
  • Establish and evolve scalable pharmacovigilance systems, processes, quality frameworks, and vendor partnerships to support a growing oncology portfolio.
  • Partner with Clinical Development, Biostatistics, Regulatory Affairs, and Medical Affairs to lead and validate safety signal assessments.
  • Communicate emerging safety information to appropriate stakeholders, including executive management and regulatory authorities, within timeframes appropriate to the benefit-risk profile.
  • Build, develop, and mentor a high-performing pharmacovigilance team across medical and operations functions, fostering scientific rigor, accountability, and patient-centered decision-making.
  • Ensure inspection readiness and compliance with global pharmacovigilance regulations, including leading root-cause analyses and CAPAs as needed.
  • Manage relationships with pharmacovigilance vendors and CROs, providing expert safety oversight of outsourced operations.

Desired Qualifications

  • Oncology drug development experience is strongly preferred.
  • Experience supporting small molecule therapeutics.
  • Prior experience preparing for or supporting commercial-stage pharmacovigilance activities.
  • Experience working in a global, outsourced operating model using CROs and external pharmacovigilance vendors, ideally in a small- to medium-sized corporate environment.
  • Demonstrated success building, scaling, or evolving a pharmacovigilance organization at a growth-stage biotech.
  • Experience supporting regulatory submissions (IND/NDA/BLA) and post-marketing safety activities.

About the Company

ORIC Pharmaceuticals

Clinical-stage oncology company targeting resistance

ORIC Pharmaceuticals is a clinical-stage cancer company focused on overcoming how cancers resist treatment. Its therapies aim to restore patients’ response to existing treatments by targeting resistance mechanisms. Lead programs include rinzimetostat (ORIC-944), an allosteric inhibitor of the PRC2 complex designed for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor that targets EGFR exon 20 and HER2 exon 20 mutations in non-small cell lung cancer. Early work continues on other resistance mechanisms across solid tumors. Unlike some competitors, ORIC concentrates specifically on breaking or bypassing resistance to current therapies, based on research from Memorial Sloan Kettering Cancer Center and brought to Nasdaq-listed status in 2020. Its goal is to improve how well existing cancer treatments work for patients by keeping cancer from outsmarting them.

Company size
51-200
Company stage
IPO
Headquarters
South San Francisco, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at ORIC Pharmaceuticals

See more jobs